ORAI1 and pulmonary arterial hypertension: In addition, in PAH-hPASMCs treated with siOrai2 or siOrai3, we found that CM5480 strongly reduced SOCE, demonstrating that SOCE in PAH-hPASMCs is mainly due to Orai1 (Supplemental Figure 8, F and G).